Vera Therapeutics (NASDAQ:VERA) Insider Robert Brenner Sells 2,151 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) insider Robert Brenner sold 2,151 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $90,298.98. Following the sale, the insider owned 50,947 shares of the company’s stock, valued at approximately $2,138,755.06. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Vera Therapeutics Stock Performance

Shares of VERA stock traded down $0.69 during trading on Wednesday, reaching $41.68. The company had a trading volume of 776,869 shares, compared to its average volume of 897,432. The firm’s 50 day simple moving average is $46.63 and its two-hundred day simple moving average is $35.30. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $56.05. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The company has a market capitalization of $2.92 billion, a PE ratio of -10.45 and a beta of 1.16.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VERA. Price T Rowe Associates Inc. MD raised its position in shares of Vera Therapeutics by 49.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after buying an additional 1,795,537 shares during the last quarter. Deerfield Management Company L.P. increased its stake in Vera Therapeutics by 8.8% during the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after acquiring an additional 293,040 shares during the period. Vanguard Group Inc. raised its holdings in Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after acquiring an additional 379,748 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after acquiring an additional 600,000 shares during the period. Finally, Eversept Partners LP lifted its position in shares of Vera Therapeutics by 9.4% in the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after acquiring an additional 264,468 shares during the period. Institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

VERA has been the topic of a number of research analyst reports. Wedbush raised their target price on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Bank of America upped their price target on shares of Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a report on Friday, December 19th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. JPMorgan Chase & Co. cut their price objective on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Finally, Evercore increased their target price on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $77.18.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.